CXCL2 and Sepsis: For example, blocking S100A9 with the inhibitor ABR-238901 greatly attenuates the CLP-induced infiltration of neutrophils, formation of edema, and expression of Mac-1, CXCL1, CXCL2 and IL-6 in the plasma or lung and improves sepsis-induced lung injury [19].